Optimizing empirical antimicrobial therapy for infection due to gram-negative pathogens in the intensive care unit: Utility of a combination antibiogram

Infection Control and Hospital Epidemiology

Volumn 31, Issue 3, 2010, Pages 256-261

  Christoff, Jennifer ^a   Tolentino, Jocelyn ^a   Mawdsley, Emily ^a   Matushek, Scott ^a   Pitrak, David ^a   Weber, Stephen G ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIINFECTIVE AGENT; CEFTAZIDIME; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATE; CONTROLLED STUDY; GRAM NEGATIVE INFECTION; HUMAN; INTENSIVE CARE UNIT;

ACADEMIC MEDICAL CENTERS; ANTI-INFECTIVE AGENTS; CHICAGO; DRUG THERAPY, COMBINATION; GRAM-NEGATIVE AEROBIC BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INTENSIVE CARE UNITS; MICROBIAL SENSITIVITY TESTS; RETROSPECTIVE STUDIES;

EID: 77249166571     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/650446     Document Type: Article

References (32)

1. Sligl W, Taylor G, Brindley PG. Five years of nosocomial gram-negative bacteremia in a general intensive care unit: epidemiology, antimicrobial susceptibility patterns, and outcomes. Int J Infect Dis 2006;10:320-325.
2. Gardiner DF, Scholand SJ, Babinchak T. Mortality and gram-negative rod bacteraemia in the intensive care unit. J Hosp Infect 2006;62:453-457.
3. Fridkin SK. Increasing prevalence of antimicrobial resistance in intensive care units. Crit Care Med 2001;29:N64-N68.
4. Flournoy DJ, Reinert RL, Bell-Dixon C, Gentry CA. Increasing antimicrobial resistance in gram-negative bacilli isolated from patients in intensive care units. Am J Infect Control 2000;28:244-250.
5. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999;115:462-474.
6. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000;118:146-155.
7. Micek ST, Lloyd AE, Ritchie DJ, Reichley RM, Fraser VJ, Kollef MH. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother 2005; 49:1306-1311.
8. Lodise TP Jr, Patel N, Kwa A, et al. Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection. Antimicrob Agents Chemother 2007;51:3510-3515.
9. Fraser A, Paul M, Almanasreh N, et al; TREAT Study Group. Benefit of appropriate empirical antibiotic treatment: thirty-day mortality and duration of hospital stay. Am J Med 2006;119:970-976.
10. Kang C, Kim A, Kim H, et al. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin Infect Dis 2003;37:745-751.
11. National nosocomial infections surveillance (NNIS) systems report, data summary from January 1992-June 2001. Am J Infect Control 2001;29:404-421.
12. Jones RN. Global epidemiology of antimicrobial resistance among communityacquired and nosocomial pathogens: a five-year summary from the SENTRY antimicrobial surveillance program (1997-2001). Semin Respir Crit Care Med 2003;24:121-134.
13. Wroblewska MM, Rudnicka J, Marchel H, Luczak M. Multidrug-resistant bacteria isolated from patients hospitalised in intensive care units. Int J Antimicrob Agents 2006;27:285-289.
14. Kollef MH. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin Infect Dis 2000;31:S131-S138.
15. Clark NM, Patterson J, Lynch JP 3rd. Antimicrobial resistance amonggram-negative organisms in the intensive care unit. Curr Opin Crit Care 2003;9:413-423.
16. Harbarth S, Nobre V, Pittet D. Does antibiotic selection impact patient outcome? Clin Infect Dis 2007;44:87-93.
17. Allan JD, Moellering RC Jr. Antimicrobial combinations in the therapy of infections due to gram-negative bacilli. Am J Med 1985;78:65-76.
18. Mouton JW. Combination therapy as a tool to prevent emergence of bacterial resistance. Infection 1999;27:S24-S28.
19. Scott RE, Robson HG. Synergistic activity of carbenicillin and gentamicin in experimental Pseudomonas bacteremia in neutropenic rats. Antimicrob Agents Chemother 1976;10:646-651.
20. Khakoo RA, Kluge RM. Effectiveness of gentamicin and carbenicillin in a rat model against infections with Pseudomonas aeruginosa resistant to gentamicin or gentamicin and carbenicillin. J Antimicrob Chemother 1979; 5:53-59.
21. Wade JC, Standiford HC, Drusano GL, et al. Potential of imipenem as single-agent empiric antibiotic therapy of febrile neutropenic patients with cancer. Am J Med 1985;78:62-72.
22. Eron LJ, Harvey L, Hixon DL, Poretz DM. Ciprofloxacin therapy of infections caused by Pseudomonas aeruginosa and other resistant bacteria. Antimicrob Agents Chemother 1985;28:308-310.
23. Verhagen C, de Pauw BE, Donnelly JP, Williams KJ, de Witte T, Janssen TH. Ceftazidime alone for treating Pseudomonas aeruginosa septicaemia in neutropenic patients. J Infect 1986;13:125-131.
24. Liang R, Yung R, Chiu E, et al. Ceftazidime versus imipenem-cislatin as initial monotherapy for febrile neutropenic patients. Antimicrob Agents Chemother 1990;34:1336-1341.
25. Chow JW, Yu VL. Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: a commentary. Int J Antimicrob Agents 1999;11:7-12.
26. Safdar N, Handelsman J, Maki DG. Does combination antimicrobial therapy reduce mortality in gram-negative bacteraemia? Ameta-analysis. Lancet Infect Dis 2004;4:519-527.
27. Paul M, Soares-Weiser K, Leibovici L. β-lactam monotherapy versus blactam- aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. BMJ 2003;326:1111.
28. Paul M, Benuri-Silbiger I, Soares-Weiser K, Leibovici L. β-lactam monotherapy versus β-lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systemic review and meta-analysis of randomized trials. BMJ 2004;328:668.
29. Leibovici L, Paul M, Poznanski O, et al. Monotherapy versus β-lactam- aminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study. Antimicrob Agents Chemother 1997;41: 1127-1133.
30. Mizuta M, Linkin DR, Nachamkin I, et al. Identification of optimal combinations for empirical dual antimicrobial therapy of Pseudomonas aeruginosa infection: potential role of a combination antibiogram. Infect Control Hosp Epidemiol 2006;27:413-415.
31. Apisarnthanarak A, Mundy LM. Role of combination antibiogram in empirical treatment of infection due to multidrug-resistant Acinetobacter baumannii. Infect Control Hosp Epidemiol 2008;29:678-679.
32. Paterson DL. Impact of antibiotic resistance in gram-negative bacilli on empirical and definitive antibiotic therapy. Clin Infect Dis 2008;47:S14-S20.